Financial News Feed

Stronger Sell Today ACRS ranks #4263 as SELL CANDIDATE. Weaker Sell
Today ACRS ranks #4263 as SELL CANDIDATE.

ACRS stock Aclaris Therapeutics

ACRS stock
Aclaris Therapeutics

Individual investors have the tendency to migrate towards certain stock strategies that have been successful in the past. While following previous strategies may be profitable, investors have to be re...

Read more

Checking up on some indicators, we can see that Aclaris Therapts (ACRS)’s last month opinion signal is 100% Sell. This is the combined signal for the previous month when applying a wide array of stu...

Read more

Tracking shares of Aclaris Therapts (ACRS), we have noted that the Parabolic SAR is currently above recent stock price levels. The Parabolic SAR is a technical indicator developed by Welles Wilder. Tr...

Read more

Investors may be focusing on technical signals for Aclaris Therapts (ACRS). Taking a look at the longer-term MACD oscillator indicator, we note that the reading is currently Sell. The MACD is generall...

Read more

Though short-term trading can be very lucrative, it can also be very risky. Short-term trading can last for only a few minutes or several days or weeks. Traders must understand the risks and the rewar...

Read more

Ichimoku traders are closely watching shares of Aclaris Therapts (ACRS) as the equity’s price has tipped below the Tenkan moving average line, creating an environment ripe for a potential near-term ...

Read more

Shares of Aclaris Therapeutics Inc. (ACRS) sank into a new 52-week low yesterday, and could be a company to watch at the open. The company’s stock fell to as low as $5.95 yesterday after opening...

Read more

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Files An 8-K Financial Statements and ExhibitsItem 9.01(a)(4) of Form 8-K. Item 9.01 Financial Statements and Exhibits. (a) Financial statements of businesses ...

Read more

Shares of Aclaris Therapeutics Inc (NASDAQ:ACRS) fell 6.5% during mid-day trading on Wednesday . The stock traded as low as $6.42 and last traded at $6.46. 673,289 shares traded hands during trading, ...

Read more

Shares of Aclaris Therapts (ACRS) are heading in a near-term negative direction as the most recent close of the company has stayed below the Balance Step. The Balance Step reading takes into account t...

Read more

Aclaris Therapeutics Inc. (ACRS) had a rough trading day for Wednesday January 16 as shares tumbled 6.51%, or a loss of $-0.45 per share, to close at $6.46. After opening the day at $6.93, shares...

Read more

Several brokerages have updated their recommendations and price targets on shares of Aclaris Therapeutics (NASDAQ: ACRS) in the last few weeks: 1/12/2019 – Aclaris Therapeutics was downgraded by ana...

Read more

After a recent scan, we have seen that the KAMA has been trending lower over the previous five trading periods for Aclaris Therapts (ACRS). Traders keeping an eye on the signal might be watching for a...

Read more

Summit Midstream Partners, LP (NYSE:SMLP) boasts a Price to Book ratio of 1.010560. This ratio is calculated by dividing the current share price by the book value per share. Investors may use Price to...

Read more

Aclaris Therapeutics (NASDAQ:ACRS) was downgraded by equities researchers at BidaskClub from a “hold” rating to a “sell” rating in a research note issued on Saturday. Several other analysts al...

Read more

News Feed powered by

Proudly made at

Rise Vilnius
in partnership with
Barclays Bank